Linked Life Data

2822429

Source:http://linkedlifedata.com/resource/pubmed/id/2822429

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1987-12-11
pubmed:abstractText
Recombinant interferon A (50 x 10(6) U/m2 three times weekly) was given to 17 patients with SCCL and 13 patients with SQL. The minimal scheduled duration of therapy was 12 weeks. Fifteen and 11 patients, respectively, were evaluable for response. All 15 patients with SCCL showed progressive disease after a period of 2.5 weeks (median; range 1-13). One patient with SQL obtained a partial remission lasting 14 months and six patients showed no change for 14-20 weeks, while the remaining patients showed progression during the initial 12 week period. Toxicity was shown to be significant and only one patient completed therapy without dose reduction. The major cause of dose reduction was fatigue and anorexia (18 patients). Fourteen patients experienced a median weight loss of 6%. Haematological and hepatological toxicity was found in six and 19 patients, respectively. In most cases parameters of marrow and liver function were reversible in spite of continuing interferon treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0277-5379
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
987-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II study.
pubmed:affiliation
Department of Oncology ONB, Finsen Institute, Copenhagen, Denmark.
pubmed:publicationType
Journal Article